Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

John D Shaughnessy

Showing results (11-20 of 148) with videos related to

Pageof 15
Sort By:
FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology|February 7, 2007
Thalidomide induces limb deformities by perturbing the Bmp/Dkk1/Wnt signaling pathwayJürgen Knobloch, John D Shaughnessy, Ulrich Rüther
Blood|November 8, 2008
Going with the flow, and beyond, in myelomaBart Barlogie, Joshua Epstein, John D Shaughnessy
The New England Journal of Medicine|September 26, 2008
Retraction: Barlogie et al. Duration of survival in patients with myeloma treated with thalidomide. N Engl J Med 2008;359:210-2Bart Barlogie, John D Shaughnessy, John Crowley
Blood|March 18, 2008
Wnt3a signaling within bone inhibits multiple myeloma bone disease and tumor growthYa-Wei Qiang, John D Shaughnessy, Shmuel Yaccoby
Human Genomics|December 14, 2011
Overview of biological database mapping services for interoperation between different 'omics' datasetsShweta S Chavan, John D Shaughnessy, Ricky D Edmondson
Bone|February 26, 2008
Dkk1-induced inhibition of Wnt signaling in osteoblast differentiation is an underlying mechanism of bone loss in multiple myelomaYa-Wei Qiang, Bart Barlogie, Stuart Rudikoff, et al.
Blood|January 25, 2007
Methylation and expression of the p16INK4A tumor suppressor gene in multiple myelomaAmel Dib, Bart Barlogie, John D Shaughnessy, et al.
Statistics in Medicine|August 8, 2007
Clustering of significant genes in prognostic studies with microarrays: application to a clinical study for multiple myelomaShigeyuki Matsui, Takeharu Yamanaka, Bart Barlogie, et al.
Blood|January 10, 2008
High-risk myeloma: a gene expression based risk-stratification model for newly diagnosed multiple myeloma treated with high-dose therapy is predictive of outcome in relapsed disease treated with single-agent bortezomib or high-dose dexamethasoneFenghuang Zhan, Bart Barlogie, George Mulligan, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 5, 2008
Tumor cell gene expression changes following short-term in vivo exposure to single agent chemotherapeutics are related to survival in multiple myelomaBart Burington, Bart Barlogie, Fenghuang Zhan, et al.
Pageof 15

Showing results (11-20 of 148) with videos related to

Sort By:
Pageof 15
FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology|February 7, 2007
Thalidomide induces limb deformities by perturbing the Bmp/Dkk1/Wnt signaling pathwayJürgen Knobloch, John D Shaughnessy, Ulrich Rüther
Blood|November 8, 2008
Going with the flow, and beyond, in myelomaBart Barlogie, Joshua Epstein, John D Shaughnessy
The New England Journal of Medicine|September 26, 2008
Retraction: Barlogie et al. Duration of survival in patients with myeloma treated with thalidomide. N Engl J Med 2008;359:210-2Bart Barlogie, John D Shaughnessy, John Crowley
Blood|March 18, 2008
Wnt3a signaling within bone inhibits multiple myeloma bone disease and tumor growthYa-Wei Qiang, John D Shaughnessy, Shmuel Yaccoby
Human Genomics|December 14, 2011
Overview of biological database mapping services for interoperation between different 'omics' datasetsShweta S Chavan, John D Shaughnessy, Ricky D Edmondson
Bone|February 26, 2008
Dkk1-induced inhibition of Wnt signaling in osteoblast differentiation is an underlying mechanism of bone loss in multiple myelomaYa-Wei Qiang, Bart Barlogie, Stuart Rudikoff, et al.
Blood|January 25, 2007
Methylation and expression of the p16INK4A tumor suppressor gene in multiple myelomaAmel Dib, Bart Barlogie, John D Shaughnessy, et al.
Statistics in Medicine|August 8, 2007
Clustering of significant genes in prognostic studies with microarrays: application to a clinical study for multiple myelomaShigeyuki Matsui, Takeharu Yamanaka, Bart Barlogie, et al.
Blood|January 10, 2008
High-risk myeloma: a gene expression based risk-stratification model for newly diagnosed multiple myeloma treated with high-dose therapy is predictive of outcome in relapsed disease treated with single-agent bortezomib or high-dose dexamethasoneFenghuang Zhan, Bart Barlogie, George Mulligan, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 5, 2008
Tumor cell gene expression changes following short-term in vivo exposure to single agent chemotherapeutics are related to survival in multiple myelomaBart Burington, Bart Barlogie, Fenghuang Zhan, et al.
Pageof 15